Zogenix’s pain is GW Pharma’s gain
A regulatory misstep puts Zogenix even further behind its epilepsy rival GW Pharma, which in turn is waiting for data that could give it another boost.
GW’s Dravet lock looks broken as Zogenix data scores
Battle in a rare form of epilepsy queued up following positive phase III trial.
Upcoming events – Zogenix and Mallinckrodt look to rare diseases
Zogenix and Mallinckrodt face investor scrutiny as they report critical data that will answer questions about safety and efficacy.
Big caps surge again in the third quarter
Teva's annus horribilis continues but overall the picture is bright.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.